Euclises
3 known investors
Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.
Investors · 3
In the news
Frequently asked questions
- What does Euclises do?
- Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.
- Who are Euclises's investors?
- Euclises's investors include iSelect Fund, Cultivation Capital, Missouri Technology Corporation.